Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian markets trade positively
Wed, 23 Sep 01:30 pm

After trading on a discouraging note during the morning session, the Indian Indices have recouped losses and are currently trading above the dotted line. Most of the sectoral indices are trading positively with stocks from the banking and mining sectors leading the gainers. However, auto stocks are witnessing maximum selling pressure.

The BSE-Sensex is trading up by 61 points (up 0.2%) and the NSE-Nifty is trading marginally up by 5 points (up 0.1%). The BSE Mid Cap index is trading flat while the BSE Small Cap index is trading up by 0.3%. Gold prices, per 10 grams, are trading at Rs 26,248 levels. Silver price, per kilogram is trading at Rs 35,234 levels. Crude oil is trading at Rs 3,077 per barrel. The rupee is trading at 65.97 to the US$.

Pharma stocks are trading on a mixed note with gains led by Dishman Pharma and Cadila Healthcare. As per an article in Reuters, Glenmark Pharmaceuticals, the Indian drug maker, is counting on strong growth in the United States to offset the weakness in emerging markets this year. The company stated that it expects to launch 10 to 12 drugs in the United States in 2016 and hopes to grow its US business by 18-20%. Those launches will include a copy of US firm Merck & Co's blockbuster cholesterol medicine Zetia for which Glenmark will be entitled to a six-month exclusivity on the market. The company has seen its profit hit in the recent quarters by current volatility in Russia, Venezuela and other emerging markets. Stock of Glenmark Pharmaceuticals is trading down by 0.4% on the BSE.

Consumer products stocks are trading mixed with Archies Ltd and Bata India bearing maximum burnt. As per a leading financial daily, shares of Pidilite Industries surged nearly 2% after the company reported that it is expected to clock close to Rs 9 bn revenue this financial year from the construction chemicals division. Moreover, the company also reported that it is planning to expand its footprint in the emerging Asian and African markets. In this regard, the company will acquire well managed businesses that will help it to expand its reach locally. Currently, the company has wholly-owned subsidiaries in Thailand, the UAE and Singapore. Stock of the company is presently trading up by 0.4%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets trade positively". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.